216 related articles for article (PubMed ID: 26310836)
1. Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: Open-label pilot study.
Takeda T; Kondo A; Koga S; Hayakawa J; Hayakawa K; Hiramatsu K; Yaegashi N
J Obstet Gynaecol Res; 2015 Oct; 41(10):1584-90. PubMed ID: 26310836
[TBL] [Abstract][Full Text] [Related]
2. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis.
Tanaka Y; Mori T; Ito F; Koshiba A; Kusuki I; Kitawaki J
Int J Gynaecol Obstet; 2016 Nov; 135(2):135-139. PubMed ID: 27477035
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
Witjes H; Creinin MD; Sundström-Poromaa I; Martin Nguyen A; Korver T
Eur J Contracept Reprod Health Care; 2015; 20(4):296-307. PubMed ID: 25712537
[TBL] [Abstract][Full Text] [Related]
4. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
Mansour D
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
[TBL] [Abstract][Full Text] [Related]
5. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
Svojanovská K
Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
[TBL] [Abstract][Full Text] [Related]
6. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.
Taniguchi F; Enatsu A; Ota I; Toda T; Arata K; Harada T
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():116-20. PubMed ID: 26115056
[TBL] [Abstract][Full Text] [Related]
7. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
Fenton C; Wellington K; Moen MD; Robinson DM
Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
[TBL] [Abstract][Full Text] [Related]
8. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
Fruzzetti F; Lazzarini V; Ricci C; Quirici B; Gambacciani M; Paoletti AM; Genazzani AR
Contraception; 2007 Sep; 76(3):190-4. PubMed ID: 17707715
[TBL] [Abstract][Full Text] [Related]
9. Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature.
Idota N; Kobayashi M; Miyamori D; Kakiuchi Y; Ikegaya H
Leg Med (Tokyo); 2015 Mar; 17(2):109-15. PubMed ID: 25454533
[TBL] [Abstract][Full Text] [Related]
10. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
12. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
[TBL] [Abstract][Full Text] [Related]
13. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
Marr J; Heinemann K; Kunz M; Rapkin A
Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
16. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits.
Machado RB; Pompei Lde M; Giribela AG; Giribela CG
Womens Health (Lond); 2011 Jan; 7(1):19-30. PubMed ID: 21175386
[TBL] [Abstract][Full Text] [Related]
17. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Bird ST; Delaney JA; Etminan M; Brophy JM; Hartzema AG
J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
[TBL] [Abstract][Full Text] [Related]
19. Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women.
Anzai Y; Heger-Mahn D; Schellschmidt I; Marr J
Contraception; 2012 Jul; 86(1):28-34. PubMed ID: 22402257
[TBL] [Abstract][Full Text] [Related]
20. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
